Iain Greenshields

GREENSHIELD ADMINISTRATION RELEASES 2023 DRUG TRENDS REPORT: THE INTRODUCTION OF NEW THERAPIES INCREASE UTILIZATION RATES

Retrieved on: 
Jeudi, octobre 19, 2023
Patient, Lisdexamfetamine, Colitis, Psoriasis, Galcanezumab, Health, Therapy, Social skills, Prevalence, Elijah Cummings Lower Drug Costs Now Act, Migraine, Methylphenidate, Rheumatoid arthritis, RA, Fremanezumab, Crohn's disease, Growth, Disease, Asthma, Pharmacy, Diabetes, Eye, Case management, Calcitonin gene-related peptide, COPD, ADHD, Appetite, Mental health, Pharmaceutical industry, Dietary supplement, Health insurance, Iain Greenshields, Semaglutide

Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.

Key Points: 
  • Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.
  • "In the ever-changing world of healthcare, GreenShield's 2023 Administration Drug Trends Report reveals a compelling narrative, with an overall rise in utilization rates - driven by new therapies and changes in how plan members approach their health," said Mark Rolnick, Executive Vice President, Head of GreenShield Administration.
  • This year's report provides data based on +32 million claims from over two million drug claimants processed by GreenShield Administration this year.
  • Beyond its annual Drug Trends report, GreenShield Administration unlocks better health for all through integrated health and benefits solutions for more than 6 million Canadians from coast-to-coast.

GREENSHIELD ADMINISTRATION RELEASES 2023 DRUG TRENDS REPORT: THE INTRODUCTION OF NEW THERAPIES INCREASE UTILIZATION RATES

Retrieved on: 
Jeudi, octobre 19, 2023
Patient, Lisdexamfetamine, Colitis, Psoriasis, Health, Therapy, Social skills, Prevalence, Elijah Cummings Lower Drug Costs Now Act, Migraine, Methylphenidate, Rheumatoid arthritis, RA, Crohn's disease, Growth, Disease, Asthma, Pharmacy, Diabetes, Eye, Case management, Calcitonin gene-related peptide, COPD, ADHD, Appetite, Mental health, Pharmaceutical industry, Dietary supplement, Health insurance, Iain Greenshields, Semaglutide

Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.

Key Points: 
  • Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.
  • "In the ever-changing world of healthcare, GreenShield's 2023 Administration Drug Trends Report reveals a compelling narrative, with an overall rise in utilization rates - driven by new therapies and changes in how plan members approach their health," said Mark Rolnick, Executive Vice President, Head of GreenShield Administration.
  • This year's report provides data based on +32 million claims from over two million drug claimants processed by GreenShield Administration this year.
  • Beyond its annual Drug Trends report, GreenShield Administration unlocks better health for all through integrated health and benefits solutions for more than 6 million Canadians from coast-to-coast.